Piperidine Derivatives as Gi-Biased Opioid Receptor Agonists
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current opioid analgesics suffer from significant side effects such as addiction, respiratory depression, constipation, tolerance, and itching, limiting their clinical use, while selective KOP and DOP receptor agonists and NOP receptor agonists have not been successfully developed due to limited analgesic efficacy and complex pharmacological effects.
Innovation Solution
Development of piperidine derivatives with high affinity and bifunctional or multifunctional effects on MOP, NOP, and/or KOP receptors, acting as G protein-biased agonists to selectively activate the G i pathway without affecting β-arrestin signaling, thereby reducing side effects and enhancing analgesic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If opioid analgesics are used to achieve strong analgesic effect, then pain relief is improved, but side effects such as addiction, respiratory depression, constipation, tolerance, and itching occur
Solution Approach 1:
The patent changes the pharmacological parameters of opioid receptor activation by designing compounds that selectively activate Gi signaling pathway while avoiding β-arrestin pathway activation. This parameter change in signaling pathway selection achieves strong analgesic effect while eliminating side effects such as addiction, respiratory depression, and constipation that are mediated by β-arrestin signaling.
Solution Approach 2:
The patent segments the opioid receptor signaling pathways into two distinct components: Gi pathway (responsible for analgesic effect) and β-arrestin pathway (responsible for side effects). By designing biased agonists that selectively activate only the Gi pathway, the patent achieves separation of analgesic effect from harmful side effects.
2Object-generated harmful factors
If selective KOP or DOP receptor agonists are used to avoid MOP receptor side effects, then addiction-related side effects are reduced, but analgesic efficacy is limited
Solution Approach 1:
The patent creates multi-functional compounds that can activate multiple opioid receptor subtypes (MOP, KOP, NOP) with different signaling biases. These compounds can selectively activate Gi pathway for analgesia while avoiding β-arrestin activation for addiction-related side effects, achieving both strong analgesic efficacy and reduced harmful effects simultaneously.
3Object-generated harmful factors
If G protein-biased μ-opioid receptor agonists are developed to activate Gi pathway without β-arrestin, then side effects are reduced, but druggability and clinical development remain challenging
Solution Approach 1:
The patent systematically modifies molecular parameters of piperidine derivatives to achieve optimal binding affinity and signaling bias. By adjusting structural parameters such as substituent groups and stereochemistry, the compounds achieve high selectivity for Gi pathway activation while maintaining good pharmacological properties for clinical development.
Data Source
Figure 1A~1B
Figure 2(A)~2(D)
AI summary
A piperidine derivative, and a pharmaceutical composition thereof, a preparation method therefor, and a use thereof. A compound of the piperidine derivative is as shown in formula (I), and definitions of substituents are detailed in the description. The piperidine derivative can be used as a bifunctional selective ligand for a µ(mu)-opioid peptide receptor (MOPR) and a κ(kappa)-opioid peptide receptor (KOPR), or a bifunctional selective ligand for a MOPR and a nociceptin opioid peptide receptor (NOPR)/opioid receptor like-1 (ORL-1) receptor. Such a compound or a pharmaceutical composition thereof can be used for treating pain, anxiety, depression, alcohol addiction, and substance abuse/dependence.